MVI welcomes positive opinion by European regulators on GSK’s Mosquirix™ (RTS,S)

Read more »

World Mosquito Day
Raising Air-Conditioned Mosquitoes to Stop Malaria

Read more »


Photo credit: PATH/Evelyn Hockstein

Partnering with us

PuzzleWe are pursuing a range of vaccine development approaches with an expanding circle of industry, academic, and government partners.

Our portfolio

MVI portfolioWe maintain a diverse portfolio of projects, including preclinical feasibility studies, translational projects, and one advanced clinical project.

View the portfolio »Subscription button

What we do and how we do it

MVI overview imageWe identify potentially promising malaria vaccine approaches and systematically move them through the development process. At the same time, we work to catalyze access to a successful malaria vaccine in the countries that need it most.

Read more »

News and announcements


RTS,S malaria vaccine Candidate receives positive scientific opinion from EMA

The European Medicines Agency’s (EMA's) Committee for Medicinal Products for Human Use has adopted a positive scientific opinion for Mosquirix™ (RTS,S), for use outside the European Union.


A first: European regulators give thumbs up to malaria candidate vaccine

On the PATH blog, Dr. David C. Kaslow discusses the latest news and next steps for the RTS,S malaria vaccine candidate.


Job opportunities at MVI

Scientific and communications openings available.


Walking together: Steve Davis reflects on 15 years of Gavi partnership

This week on Gavi’s blog, Steve Davis, president and CEO of PATH, provided insight on what it takes to develop and strengthen a global community of scientists, policymakers, advocates, regulators, medical workers, and caregivers to continue our good work.

Events and Conferences

ASTMH 64th Annual Meeting
October 25–29, 2015